Fosfomycin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Fosfomycin: From Uncomplicated Urinary Tract Infection to Pyelitis
One-Sentence Summary
Fosfomycin is a broad-spectrum bactericidal antibiotic with a well-established role in treating uncomplicated lower urinary tract infections, acting through irreversible inhibition of the MurA enzyme to block bacterial cell wall synthesis. Among 10 TxGNN-predicted new indications, pyelitis (upper urinary tract infection / acute pyelonephritis) is the most clinically actionable candidate, supported by a completed Phase 3 RCT (ZEUS trial) and a 2025 systematic review with network meta-analysis. The drug is currently not marketed in Canada, meaning any clinical access requires the Health Canada Special Access Programme.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Uncomplicated urinary tract infection (cystitis) |
| Featured Predicted Indication | Pyelitis / Acute Pyelonephritis |
| TxGNN Prediction Score | 99.37% (Rank #10 among 10 predictions) |
| Evidence Level | L1 |
| Canada Market Status | Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Proceed with Guardrails |
Note on TxGNN Ranking: The highest-scored TxGNN prediction (Ureaplasma urethritis, Rank #1, 99.99%) has a fundamental mechanistic barrier — Ureaplasma urealyticum is a cell wall-deficient organism, making fosfomycin’s MurA-targeting mechanism entirely ineffective. Similarly, Rank #6 (urogenital tuberculosis) has no biological plausibility — Mycobacterium tuberculosis is intrinsically resistant to fosfomycin. The most clinically actionable prediction is pyelitis (Rank #10), which carries the highest evidence level (L1).
Why is This Prediction Reasonable?
Fosfomycin is an epoxide antibiotic that irreversibly inactivates MurA (UDP-N-acetylglucosamine-3-enolpyruvyltransferase), the enzyme catalyzing the first committed step of bacterial peptidoglycan biosynthesis. This mechanism is entirely distinct from β-lactams, fluoroquinolones, and aminoglycosides, which explains its retained potency against multidrug-resistant organisms including ESBL-producing E. coli, carbapenem-resistant Enterobacteriaceae, and vancomycin-resistant Enterococcus. Against the major uropathogens — E. coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterococcus faecalis — fosfomycin maintains favorable MIC distributions with low cross-resistance rates.
Pyelitis and acute pyelonephritis are upper urinary tract infections sharing the same causative pathogens as uncomplicated cystitis, predominantly E. coli (60–80% of cases). The step from lower to upper tract treatment is pharmacokinetically well-supported: approximately 90% of absorbed fosfomycin is excreted unchanged in urine, achieving concentrations exceeding 1,000 μg/mL — far above the MIC₉₀ for common uropathogens. Intravenous fosfomycin disodium additionally achieves therapeutic concentrations in renal parenchymal tissue, which is essential for upper tract infections. These pharmacokinetic properties create a direct mechanistic bridge from uncomplicated cystitis to pyelitis.
The Phase 3 ZEUS trial directly compared IV fosfomycin (ZTI-01) with piperacillin-tazobactam in patients with complicated UTI including acute pyelonephritis and demonstrated non-inferiority in clinical cure rates. A 2025 systematic review and network meta-analysis further confirmed this efficacy across comparators. The clinical significance of fosfomycin’s preserved activity against ESBL-producing organisms — increasingly responsible for hospital-acquired and community-onset pyelonephritis — makes this prediction particularly timely in the context of antimicrobial stewardship.
Clinical Trial Evidence
No clinical trials specifically targeting pyelitis are registered in ClinicalTrials.gov in the current evidence pack. The pivotal Phase 3 RCT evidence (ZEUS trial) exists as published literature — see the Literature Evidence section below for full details.
The only ClinicalTrials.gov entries retrieved across all 10 predicted indications were two broad pediatric PK/PD safety studies (NCT04278404, NCT01431326) identified under “uterine inflammatory disease.” Both studies enrolled thousands of children to characterize general pharmacokinetics of understudied drugs — neither was designed to evaluate fosfomycin efficacy for any specific indication in this evidence pack.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30861061 | 2019 | Phase 3 RCT | Clin Infect Dis | ZEUS trial: IV fosfomycin (ZTI-01) non-inferior to piperacillin-tazobactam for complicated UTI including acute pyelonephritis |
| 27064136 | 2016 | RCT | Clin Microbiol Infect | Fosfomycin trometamol (3g × 3 doses) effective for uncomplicated gonococcal urethritis in men (N=126); directly validates Rank #2 prediction |
| 39817442 | 2025 | Systematic Review / NMA | J Comp Effectiveness Research | Fosfomycin confirmed efficacious for cUTI/acute pyelonephritis vs. carbapenems and other agents in network meta-analysis |
| 33819054 | 2021 | Clinical Guidelines | Ann Intern Med | ACP best practices recommend short-course antibiotics for UTIs; fosfomycin endorsed as first-line for uncomplicated cystitis |
| 36031053 | 2023 | Review | Clin Microbiol Infect | Fosfomycin recommended for UTI in pregnancy including upper tract infections; international guideline summary |
| 32303061 | 2020 | Retrospective Cohort | J Antimicrob Chemother | Real-world oral fosfomycin use for pyelonephritis and cUTI over 1 year in a large municipal system; limited data but used clinically |
| 35141335 | 2022 | Cohort Study | BioMed Res Int | Fosfomycin therapeutic efficacy validated in ESBL-producing E. coli acute pyelonephritis mouse model |
| 31494827 | 2019 | Systematic Review (PK/PD) | Eur J Clin Microbiol Infect Dis | PK/PD target attainment analysis for oral antibiotics in pyelonephritis; fosfomycin assessed for resistant E. coli |
| 31160291 | 2019 | Preclinical Study | Antimicrob Agents Chemother | Oral fosfomycin shows unexpected activity against resistant E. coli strains (MIC up to 256 μg/mL) in murine pyelonephritis model |
| 31608743 | 2020 | Narrative Review | Postgraduate Medicine | Fosfomycin 3g single dose listed as first-line for uncomplicated cystitis; discussed as rescue option for MDR uropathogens |
Canada Market Information
Fosfomycin is not currently marketed in Canada and holds no approved Drug Identification Numbers (DINs) with Health Canada.
Fosfomycin is commercially available in other jurisdictions: IV formulation (fosfomycin disodium/ZTI-01, marketed as CONTEPO®) is approved in the United States for cUTI; oral formulation (fosfomycin trometamol 3g sachets) is widely available in Europe, Japan, and Latin America. Canadian healthcare facilities seeking access would need to apply through Health Canada’s Special Access Programme (SAP).
Safety Considerations
Please refer to the package insert for safety information.
Safety data — including key warnings, contraindications, and drug-drug interactions — was not available in this evidence pack. A formal review of the complete SmPC or package insert is a prerequisite before any clinical application and is listed as a required action in the Next Steps below.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The ZEUS Phase 3 RCT demonstrated non-inferiority of IV fosfomycin versus piperacillin-tazobactam for complicated UTI including acute pyelonephritis, and a 2025 systematic review with network meta-analysis independently confirms this efficacy. Fosfomycin’s unique mechanism of action, favorable pharmacokinetics (>90% renal excretion, urine concentrations >1,000 μg/mL), and preserved activity against ESBL-producing and MDR uropathogens create a compelling clinical case — especially where standard first-line agents have failed due to resistance. The drug is not marketed in Canada, which is the principal guardrail governing access.
To proceed, the following is needed:
- Regulatory access: File a Health Canada Special Access Programme (SAP) application specifying the target formulation (IV fosfomycin disodium for hospitalized pyelonephritis, or oral fosfomycin trometamol for outpatient use)
- Safety review: Obtain and formally evaluate the complete package insert for contraindications, warnings, and drug interactions — this data is entirely absent from the current evidence pack and is classified as a blocking gap
- Local susceptibility data: Confirm fosfomycin MIC distributions and resistance rates for local E. coli, Klebsiella, and Proteus isolates before considering empiric use
- Formulation and route decision: Define whether IV (for hospitalized acute pyelonephritis) or oral (for selected outpatient complicated UTI) formulation is the intended use case, as clinical evidence and dosing regimens differ substantially between routes
- Secondary research question — Gonococcal urethritis: Rank #2 prediction has RCT-level evidence (PMID 27064136) supporting fosfomycin trometamol for uncomplicated gonococcal urethritis in men — rated Research Question. This warrants active monitoring given escalating N. gonorrhoeae resistance to fluoroquinolones and extended-spectrum cephalosporins; fosfomycin may represent a viable salvage option if resistance to current first-line agents continues to rise
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.